Response monitoring of infant acute myeloid leukemia treatment by quantification of the tumor specific MLL-FNBP1 fusion gene

Leuk Lymphoma. 2015 Mar;56(3):793-6. doi: 10.3109/10428194.2014.928933. Epub 2014 Jul 17.

Authors

Manuela Krumbholz¹, Ronny Jung, Jutta Bradtke, Dirk Reinhardt, Daniel Stachel, Markus Metzler

Affiliation

¹ Department of Pediatrics, University Hospital Erlangen , Erlangen , Germany.

PMID: 24884312
DOI: 10.3109/10428194.2014.928933

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Acute Disease
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carrier Proteins / genetics*
Cytarabine / administration & dosage
Fatty Acid-Binding Proteins
Female
Humans
In Situ Hybridization, Fluorescence
Infant
Karyotype
Leukemia, Myeloid / diagnosis
Leukemia, Myeloid / drug therapy
Leukemia, Myeloid / genetics*
Mitoxantrone / administration & dosage
Myeloid-Lymphoid Leukemia Protein / genetics*
Oncogene Proteins, Fusion / genetics*
Remission Induction
Treatment Outcome

Substances

Carrier Proteins
FNBP1 protein, human
Fatty Acid-Binding Proteins
Oncogene Proteins, Fusion
Cytarabine
Myeloid-Lymphoid Leukemia Protein
Mitoxantrone